Gossamer Bio’s potential Winrevair competitor fails pivotal trialnews2026-02-23T13:00:43+00:00February 23rd, 2026|Endpoints News|
Novo Nordisk’s CagriSema beaten by Lilly’s Zepbound in head-to-head obesity trialnews2026-02-23T10:03:49+00:00February 23rd, 2026|Endpoints News|
MoonLake has ‘confidence’ ahead of FDA submission, discloses mid-stage arthritis winnews2026-02-22T16:00:51+00:00February 22nd, 2026|Endpoints News|
Ionis scraps Alzheimer’s drug for people with Down syndromenews2026-02-20T19:32:53+00:00February 20th, 2026|Endpoints News|
Obesity biotech Verdiva plans big year of data, explores dealsnews2026-02-19T16:47:40+00:00February 19th, 2026|Endpoints News|
J&J pauses patient recruitment in mid-stage trial of AC Immune’s Alzheimer’s drugnews2026-02-19T11:55:09+00:00February 19th, 2026|Endpoints News|
Compass Pathways soars on second Phase 3 depression hitnews2026-02-17T15:38:26+00:00February 17th, 2026|Endpoints News|
Ocular Therapeutix’ Axpaxli shows superiority over Eylea, shares sinknews2026-02-17T12:05:11+00:00February 17th, 2026|Endpoints News|
Boehringer Ingelheim stops work on inhaled cystic fibrosis gene therapynews2026-02-17T11:03:37+00:00February 17th, 2026|Endpoints News|
Pentagon adds, then withdraws, WuXi AppTec to Chinese military listnews2026-02-13T18:48:38+00:00February 13th, 2026|Endpoints News|
